Case report reveals refractory pityriasis rubra pilaris was effectively treated with tofacitinib, suggesting JAK inhibitors may be a viable option.
Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disorder that can severely impact the quality of life in patients, particularly when presenting in chronic or refractory form. Emerging evidence suggests that JAK inhibitors may offer a potential treatment option. Here, we present a case of refractory PRP successfully treated with tofacitinib.
No takes yet. Share an insight, caveat, or question.
Taremi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: